ABVD三周期后PET适应治疗用于各期霍奇金淋巴瘤:GATLA LH-05试验结果
本研究纳入Ⅰ~Ⅳ期经典霍奇金淋巴瘤患者,接受3周期ABVD后行中期PET(PET3),PET3阴性者不再治疗,阳性者追加3周期ABVD联合受累野放疗或挽救化疗。239例早期和138例晚期患者可评估,260例(70%)PET3阴性,其3年无进展生存率和总生存率均高于PET3阳性者,且各分期PET3阴性者结局相似。
要点
- 3周期ABVD后PET3阴性者占70%,3年PFS为90% vs 65%(P<0.0001),OS为98% vs 92%(P=0.007)。
- PET3阴性者无论诊断分期,3年PFS为90-91%(P=0.76)、OS为97-99%。
- PET3阴性是PFS唯一独立预后因素(HR 3.8,95%CI 2.4-6.3,P<0.0001)。
核心结论
- 本研究提示,ABVD后PET3阴性的经典霍奇金淋巴瘤患者无论诊断分期如何结局均良好。
- 需开展把握度充分的Ⅲ期试验以确认这些发现。
研究设计与样本
- GATLA LH-05试验纳入Ⅰ~Ⅳ期经典霍奇金淋巴瘤患者,接受3周期ABVD后行中期PET(PET3)。
- PET3阴性者不再进一步治疗;PET3阳性者接受3周期额外ABVD联合受累野放疗,若对ABVD难治则接受挽救化疗,并以PET(PET6)重新评估。
- 239例早期和138例晚期患者可评估;研究终点为3年无进展生存率和总生存率。
主要发现
- 260例(70%)为PET3阴性,其3年PFS为90% vs PET3阳性者65%(P<0.0001),3年OS为98% vs 92%(P=0.007)。
- 所有PET3阴性患者无论诊断分期,3年PFS为90-91%(P=0.76)、OS为97-99%。
- PFS唯一独立预后因素为PET3阴性(HR 3.8,95%CI 2.4-6.3,P<0.0001)。
临床怎么用
- 作者认为,ABVD后PET3阴性的经典霍奇金淋巴瘤患者无论诊断分期结局均良好。
- 作者指出需开展把握度充分的Ⅲ期试验以确认这些发现。
局限性
- 原文指出需开展把握度充分的Ⅲ期试验以确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I-IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3-negative patients received no further therapy. PET3-positive patients received three additional cycles of ABVD plus involved-field radiation therapy or salvage chemotherapy, if refractory to ABVD, and were re-evaluated by PET scan (PET6). Study endpoints were 3-year progression-free survival (PFS) and overall survival (OS) rates. Two hundred and thirty-nine patients with early-stage and 138 with advanced-stage were evaluable. Overall, 260 patients (70%) were PET3-negative and had higher 3-year PFS (90% vs. 65%; P < 0·0001) and OS (98% vs. 92%; P = 0·007) rates than PET3-positive patients. All PET3-negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90-91%; P = 0·76) and OS (97-99%). The only independent prognostic factor for PFS was PET3-negativity (Hazard ratio 3·8; 95% confidence interval 2·4-6·3; P < 0·0001). This study suggests that cHL patients who achieve a negative PET3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings.
引用
- Pavlovsky A, Fernandez I, Kurgansky N, et al. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Br J Haematol. 2019. PMID: 30864146. doi:10.1111/bjh.15838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。